Zepbound (tirzepatide) available in US pharmacies for adults living with obesity
top of page
Browse by category
Search
Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...
Roche poised to enter anti-obesity medication market with agreement to acquire Carmot Therapeutics
Roche is poised to enter the lucrative anti-obesity medication market after entering into a definitive merger agreement to acquire Carmot...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM
Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...
AstraZeneca enters obesity market with $2b deal for GLP-1 candidate
AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...
Lilly's Mounjaro (tirzepatide) receives UK marketing authorisation for weight management
Eli Lilly and Company has granted marketing authorisation (MA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for...
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
Browse by tag
bottom of page